Company: NDRA
Filing Date: 2025-10-30
Form Type: 424B5
Source: 0001213900-25-103705
Chunk: 16

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-10-30
Form: 424B5
Chunk 16
---
, and our use of the proceeds may
not yield any return on your investment. Because of the number and variability of factors that will determine our use of the net proceeds
from this offering, their ultimate use may vary substantially from their currently intended use. Our failure to apply the net proceeds
of this offering effectively could compromise our ability to pursue our growth strategy and we might not be able to yield a significant
return, if any, in our investment of these net proceeds. You will not have the opportunity to influence our decisions on how to use our
net proceeds from this offering.

The common stock offered hereby will be sold in“at-the-market” offerings, and investors who buy shares at different times will likely pay different prices.

Investors who purchase shares in this offering
at different times will likely pay different prices, and so may experience different outcomes in their investment results. We will have
discretion, subject to market demand, to vary the timing, prices, and numbers of shares sold, and there is no minimum or maximum sales
price. Investors may experience a decline in the value of their shares as a result of share sales made at prices lower than the prices
they paid.

The actual number of shares we will issue under the Sales Agreement, at any one time or in total, is uncertain.

Subject to certain limitations in the Sales Agreement
and compliance with applicable law, we have the discretion to deliver a sales notice to the Sales Agent at any time throughout the term
of the Sales Agreement. The number of shares that are sold by the Sales Agent after we deliver a sales notice will fluctuate based on
the market price of the common stock during the sales period and limits we set with the Sales Agent. Because the price per share of each
share sold will fluctuate based on the market price of our common stock during the sales period, it is not possible at this stage to predict
the number of shares, if any, that will ultimately be issued.

Our stock price and trading volume has fluctuated in the past, has recently been volatile and may be volatile in the future for reasons unrelated to our operating performance or prospects, and as a result, investors in our common stock could incur substantial losses.

Our stock price has fluctuated in the past, has
recently been volatile and may be volatile in the future. From January 1, 2025 through September 30, 2025, intra-day trading prices of
shares of our common stock on the Nasdaq Capital Market fluctuated from a low of